Investor
Sio Capital Management, LLC
CIK 0001482416 · filed 2026-05-14 · SEC filing
13F book
$697.3M
Positions
73
22 new · 14 sold
Largest name
7.1%
Maximus, Inc. · MMS
Est. mark
−$10.8M
Price effect on 51 names still held. Flow $101.5M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Maximus, Inc. | MMS | 768.8K | $49.3M | 7.1% | −$11.1M | Added$6.1M |
| Waystar Hldg Corp | — | 1.64M | $39.6M | 5.7% | −$5.3M | Added$19.5M |
| Icon Plc | ICLR | 306.4K | $33.9M | 4.9% | −$9.1M | Added$10.7M |
| Cencora, Inc. | COR | 100.9K | $31.7M | 4.5% | −$375.4K | Added$26.3M |
| Dianthus Therapeutics Inc | — | 370K | $31.1M | 4.5% | $15.8M | Cut$11.5M |
| Anteris Technologies Global Corp. | AVR | 5.38M | $29.9M | 4.3% | $1.05M | Added$20.5M |
| Corcept Therapeutics Inc | CORT | 674.8K | $27.2M | 3.9% | — | New |
| Livanova Plc | LIVN | 421.6K | $26.8M | 3.8% | $654.4K | Added$6.96M |
| Tyra Biosciences, Inc. | TYRA | 605.4K | $23.2M | 3.3% | $6.32M | Added$9.36M |
| Celcuity Inc. | CELC | 193.8K | $22.1M | 3.2% | $2.79M | Cut−$25.5M |
| Gsk Plc | — | 385.9K | $21.3M | 3.1% | — | New |
| Ani Pharmaceuticals Inc | ANIP | 265.5K | $20.4M | 2.9% | −$178K | Added$13.5M |
| Abbott Labs | ABT | 186.6K | $19.2M | 2.7% | — | New |
| Embecta Corp. | EMBC | 1.85M | $16.3M | 2.3% | — | New |
| Abivax Sa | — | 135.8K | $15.1M | 2.2% | −$1.01M | Added$9.31M |
| Vir Biotechnology, Inc. | VIR | 1.5M | $13.4M | 1.9% | $1.4M | Added$10.5M |
| Haemonetics Corp Mass | — | 220.7K | $12.4M | 1.8% | −$2.2M | Added$5.01M |
| Sionna Therapeutics, Inc. | SION | 294.3K | $11.8M | 1.7% | — | New |
| Sanofi Sa | — | 239.7K | $11.5M | 1.7% | −$67.1K | Cut−$35.5M |
| Rapport Therapeutics, Inc. | RAPP | 366.8K | $11.5M | 1.6% | $176K | Added$5.86M |
| Teleflex Inc | TFX | 94.8K | $11.3M | 1.6% | −$211.1K | Added$736.7K |
| Biomarin Pharmaceutical Inc | BMRN | 194.2K | $11M | 1.6% | −$571K | Cut−$2.86M |
| Cross Ctry Healthcare Inc | — | 1.1M | $10.3M | 1.5% | $1.39M | Added$1.67M |
| Protara Therapeutics, Inc. | TARA | 1.97M | $10.3M | 1.5% | −$205.8K | Added$1.12M |
| Structure Therapeutics Inc. | GPCR | 209.1K | $10.1M | 1.4% | −$4.3M | Added−$3.94M |
| Biohaven Ltd. | BHVN | 1.16M | $9.85M | 1.4% | −$3.29M | Cut−$4.21M |
| Monopar Therapeutics | MNPR | 173.5K | $9.51M | 1.4% | — | New |
| EyePoint, Inc. | EYPT | 721.8K | $9.3M | 1.3% | — | New |
| Crinetics Pharmaceuticals In | — | 249.9K | $9.08M | 1.3% | −$1.28M | Added$3.26M |
| Edgewise Therapeutics, Inc. | EWTX | 269K | $8.47M | 1.2% | $1.59M | Added$2.58M |
| Compass Pathways Plc | CMPS | 1.51M | $8.33M | 1.2% | — | New |
| Ocular Therapeutix, Inc | OCUL | 968.6K | $8.2M | 1.2% | — | New |
| Aquestive Therapeutics, Inc. | AQST | 1.92M | $7.98M | 1.1% | −$2.29M | Added$1.56M |
| Relmada Therapeutics, Inc. | RLMD | 965K | $6.72M | 1.0% | — | New |
| Oruka Therapeutics, Inc. | ORKA | 132.5K | $6.5M | 0.9% | $2.21M | Added$2.92M |
| Zenas BioPharma, Inc. | ZBIO | 331.7K | $6.49M | 0.9% | — | New |
| Bright Minds Biosciences Inc. | DRUG | 86.1K | $6.28M | 0.9% | −$415.1K | Added−$108.7K |
| Quidelortho Corp | QDEL | 359K | $5.9M | 0.8% | — | New |
| Zimmer Biomet Holdings, Inc. | ZBH | 62.6K | $5.66M | 0.8% | $31.3K | Cut−$29M |
| Replimune Group, Inc. | REPL | 720K | $5.51M | 0.8% | — | New |
| Organon & Co. | OGN | 865.9K | $5.19M | 0.7% | −$1.02M | Cut−$19.3M |
| OnKure Therapeutics, Inc. | OKUR | 1.08M | $4.47M | 0.6% | — | New |
| Disc Medicine, Inc. | IRON | 65.2K | $4.17M | 0.6% | −$890.9K | Added−$403.8K |
| PMV Pharmaceuticals, Inc. | PMVP | 3.08M | $3.81M | 0.5% | −$26.4K | Added$519.3K |
| Immunome Inc. | IMNM | 165.1K | $3.61M | 0.5% | — | New |
| Integra Lifesciences Hldgs C | — | 383.1K | $3.61M | 0.5% | — | New |
| Savara Inc | SVRA | 613.9K | $3.35M | 0.5% | −$349.9K | Held |
| Proqr Thrapeutics N V | — | 1.95M | $3.17M | 0.5% | −$781.9K | Cut−$1.21M |
| Shoulder Innovations, Inc. | SI | 210.6K | $3.06M | 0.4% | $48.4K | Cut−$199.4K |
| Ovid Therapeutics Inc. | OVID | 1.25M | $2.78M | 0.4% | $738.9K | Cut$453.5K |
| Kymera Therapeutics, Inc. | KYMR | 32.2K | $2.68M | 0.4% | $176.6K | Held |
| Aligos Therapeutics, Inc. | ALGS | 327.2K | $2.43M | 0.3% | −$618.5K | Cut−$699.6K |
| Context Therapeutics Inc. | CNTX | 917.9K | $2.4M | 0.3% | $1.06M | Cut$432.8K |
| AN2 Therapeutics, Inc. | ANTX | 657.2K | $2.25M | 0.3% | — | New |
| Serina Therapeutics, Inc. | SER | 1M | $1.94M | 0.3% | — | New |
| iBio, Inc. | IBIO | 904.3K | $1.72M | 0.2% | −$22.2K | Added$289.9K |
| Adagio Med Hldgs Inc | — | 1.29M | $1.48M | 0.2% | $141.7K | Held |
| Xilio Therapeutics, Inc. | XLO | 152.5K | $1.28M | 0.2% | — | New |
| Bridgebio Oncology Therapeut | — | 130.6K | $1.17M | 0.2% | −$466.3K | Held |
| Hyperfine, Inc. | HYPR | 1M | $1.08M | 0.2% | $100.7K | Cut−$878.6K |
| Senseonics Hldgs Inc | — | 115.8K | $771.1K | 0.1% | $132K | Held |
| Foghorn Therapeutics Inc. | FHTX | 122.9K | $587.4K | 0.1% | −$76.2K | Held |
| Terns Pharmaceuticals Inc | — | 10.1K | $532.5K | 0.1% | $124.4K | Held |
| Enanta Pharmaceuticals Inc | ENTA | 40K | $505.2K | 0.1% | −$125.6K | Held |
| TELA Bio, Inc. | TELA | 636.3K | $394.5K | 0.1% | −$356.3K | Held |
| Neuroone Med Technologies Co | — | 496.6K | $385.6K | 0.1% | $9.19K | Cut−$478.5K |
| Boundless Bio, Inc. | BOLD | 163.7K | $180K | 0.0% | −$16.4K | Held |
| Nyxoah S A | — | 50.8K | $148.4K | 0.0% | −$85.4K | Held |
| Modular Med Inc | — | 26.2K | $138.3K | 0.0% | — | New |
| Erasca, Inc. | ERAS | 5K | $80.9K | 0.0% | — | New |
| Rocket Pharmaceuticals Inc | — | 400K | $7.02K | 0.0% | −$180 | Held |
| Humacyte Inc | — | 50K | $4.57K | 0.0% | −$303 | Held |
| Simulations Plus, Inc. | SLP | 200 | $2.36K | 0.0% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.